We conduct basic medical and scientific research on three areas:
Cancer arises in a multi-step process in which normal cells acquire mutations through the activation of oncogenes and the loss of tumor suppressive mechanisms. We are interested in examining the signaling pathways in cancer cells to understand the complex molecular events leading to tumor growth, invasion, metastasis, and immune evasion.
Cell death (apoptosis) is a part of life. Each day millions of cells die and are cleared via efferocytosis, a process characterized by the engulfment of apoptotic cells in a manner that maintains tolerance. Cell death is also very important in the tumor microenvironment whereby highly proliferating tumors have equally high rates of apoptosis, necessitating the demand for phagocytic cells to engulf apoptotic cells. In addition to dying apoptotic cells, the metabolic stress that occurs in the tumor also induces PS-externalization on living cells in the tumor microenvironment, including viable tumor cells, vascular endothelial cells and infiltrating immune cells. As a result, PS is constitutively externalized in solid tumors, likely agnostically to tumor type, that creates a global immunosuppressive environment that impairs host anti-tumor immunity. Our laboratory is interesting in the basic molecular mechanisms that promote PS externalization in the tumor microenvironment, as well as how PS signals to PS receptors that include members of the TAM family of receptor tyrosine kinases (Tyro3, Axl, and Mertk), and how PS can be therapeutically targeted with PS-targeting mAbs and novel PS-targeting interferons. Our multidisciplinary approaches set out to develop anti-cancer therapeutics that target PS and PS receptors in the tumor microenvironment, with the hope they will act akin to immune checkpoint inhibitors to activate tumor immunity.
Crk is a small SH2 and SH3 domain containing protein and one of the most versatile genes in cells. Using these domains to assemble multi-functional protein complexes, Crk binds an astonishing number of proteins involved in cell proliferation and cell motility. The significance of Crk in human cancers has been enumerated in recent years. It is now apparent that Crk is overexpressed in several carcinomas and sarcomas, including breast cancer, lung cancer, glioblastoma, gastric cancer, synovial sarcoma, and ovarian cancer. We have observed that the level of Crk expression correlates with aggressive and malignant phenotypes as well as a more advanced stage of cancer, and recently that Crk can induce the up-regulation of PDL1 on tumor cells. Our research employs structural biology, molecular biology, mass spectrometry, and animal cancer models to examine and analyze Crk and its function in invasion and metastasis.